LON:NFX Nuformix (NFX) Share Price, News & Analysis GBX 0.17 0.00 (0.00%) As of 12:09 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsBuy This Stock About Nuformix Stock (LON:NFX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuformix alerts:Sign Up Key Stats Today's Range 0.17▼ 0.2250-Day Range 0.16▼ 0.2152-Week Range 0.01▼ 0.56Volume52.82 million shsAverage Volume38.32 million shsMarket Capitalization£4.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom. Read More Receive NFX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuformix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NFX Stock News HeadlinesNuformix (LON:NFX) Shares Up 5.5% - Time to Buy?May 29, 2026 | americanbankingnews.comNuformix Advances Inhaled Fibrosis Therapy Following Orphan Drug Milestones and New Funding Support (NFX)May 28, 2026 | uk.finance.yahoo.comOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown.June 8 at 1:00 AM | Behind the Markets (Ad)Nuformix updates market on enlarged share capital and voting rightsMarch 31, 2026 | tipranks.comNuformix shares jump 12.5% as FDA grants orphan drug status for rare lung disease programmeMarch 10, 2026 | uk.finance.yahoo.comNuformix PLCFebruary 26, 2026 | marketwatch.comNuformix plc Successfully Completes Oversubscribed Open OfferNovember 12, 2025 | tipranks.comDr Dan Gooding, Nuformix, increasingly confident US regulators will grant NXP002 Orphan Drug StatusOctober 14, 2025 | lse.co.ukSee More Headlines NFX Stock Analysis - Frequently Asked Questions How have NFX shares performed this year? Nuformix's stock was trading at GBX 0.25 at the beginning of 2026. Since then, NFX shares have decreased by 32.7% and is now trading at GBX 0.17. How were Nuformix's earnings last quarter? Nuformix plc (LON:NFX) released its quarterly earnings results on Thursday, May, 28th. The company reported ($0.02) earnings per share (EPS) for the quarter. How do I buy shares of Nuformix? Shares of NFX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Nuformix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuformix investors own include Rolls-Royce Holdings plc (RR), UK Oil & Gas (UKOG), Ampliphi Biosciences (APHB), Argo Blockchain (ARB) and Ardelyx (ARDX). Company Calendar Last Earnings5/28/2026Today6/08/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:NFX Previous SymbolLON:LVRT CIKN/A Webwww.levrett.com Phone44 1223 423 667FaxN/AEmployees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£383.40 thousand Net MarginsN/A Pretax MarginN/A Return on Equity-83.53% Return on Assets-17.20% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio3.35 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 0.05 per share Price / Cash Flow3.55 Book ValueGBX 0.54 per share Price / Book0.31Miscellaneous Outstanding Shares2,609,749,000Free FloatN/AMarket Cap£4.41 million OptionableNot Optionable Beta1.55 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (LON:NFX) was last updated on 6/8/2026 by MarketBeat.com Staff. From Our PartnersThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored$36 million a day says something big is comingInstitutional capital is flowing into one thesis at a rate of $36 million per day - $25,000 every single minut...Porter & Company | SponsoredOne hidden supplier shipped 5 billion parts to SpaceXMost investors are focused on the historic $1.75 trillion SpaceX IPO expected around June 30. But there's a le...Weiss Ratings | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHave you tried Elon Musk’s 70X AI agent?Jeff Brown picked Nvidia in 2016 - it's up 25,155% since. He recommended Bitcoin at $240 - it's up 31,219% sin...Brownstone Research | SponsoredJune 12th. After That, This Is Gone.A small publicly traded company holds $9 billion in private SpaceX shares from a 2023 Starlink deal - and it's...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuformix plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuformix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
